These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 34752187)

  • 1. The expression of PHOX2B in bone marrow and peripheral blood predicts adverse clinical outcome in non-high-risk neuroblastoma.
    Fan H; Xing T; Hong H; Duan C; Zhao W; Zhao Q; Wang X; Huang C; Zhu S; Jin M; Su Y; Gao C; Ma X
    Pediatr Hematol Oncol; 2022 May; 39(4):343-356. PubMed ID: 34752187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: a European HR-NBL1/SIOPEN study.
    Viprey VF; Gregory WM; Corrias MV; Tchirkov A; Swerts K; Vicha A; Dallorso S; Brock P; Luksch R; Valteau-Couanet D; Papadakis V; Laureys G; Pearson AD; Ladenstein R; Burchill SA
    J Clin Oncol; 2014 Apr; 32(10):1074-83. PubMed ID: 24590653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective investigation of applicability and the prognostic significance of bone marrow involvement in patients with neuroblastoma detected by quantitative reverse transcription PCR.
    Druy AE; Shorikov EV; Tsaur GA; Popov AM; Zaychikov AN; Tuponogov SN; Saveliev LI; Tytgat GAM; Fechina LG
    Pediatr Blood Cancer; 2018 Nov; 65(11):e27354. PubMed ID: 30007008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Event-free survival of infants and toddlers enrolled in the HR-NBL-1/SIOPEN trial is associated with the level of neuroblastoma mRNAs at diagnosis.
    Corrias MV; Parodi S; Tchirkov A; Lammens T; Vicha A; Pasqualini C; Träger C; Yáñez Y; Dallorso S; Varesio L; Luksch R; Laureys G; Valteau-Couanet D; Canete A; Pöetschger U; Ladenstein R; Burchill SA
    Pediatr Blood Cancer; 2018 Jul; 65(7):e27052. PubMed ID: 29603574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma.
    Stutterheim J; Gerritsen A; Zappeij-Kannegieter L; Kleijn I; Dee R; Hooft L; van Noesel MM; Bierings M; Berthold F; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
    J Clin Oncol; 2008 Nov; 26(33):5443-9. PubMed ID: 18838715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of β-catenin and paired-like homeobox 2B (PHOX2B) expression in neuroblastoma patients; predictive and prognostic value.
    El-Shazly SS; Hassan NM; Abdellateif MS; El Taweel MA; Abd-Elwahab N; Ebeid EN
    Exp Mol Pathol; 2019 Oct; 110():104272. PubMed ID: 31220430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prognostic value of the determination of bone marrow lesion in patients with neuroblastoma based on the gene PHOX2B and TH expression].
    Druĭ AE; Shorikov EV; Tsaur GA; Popov AM; Tuponogov SN; Savel'ëv LI; Tsvirenko SV; Fechina LG
    Vopr Onkol; 2014; 60(2):57-62. PubMed ID: 24919263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined analysis of PHOX2B at two time points and its value for further risk stratification in high-risk neuroblastoma.
    Yue Z; Gao C; Xing T; Zhao W; Duan C; Wang X; Jin M; Su Y
    Pediatr Blood Cancer; 2023 May; 70(5):e30261. PubMed ID: 36815592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of neuroblastoma cells in bone marrow and peripheral blood at diagnosis by the reverse transcriptase-polymerase chain reaction for tyrosine hydroxylase mRNA.
    Miyajima Y; Kato K; Numata S; Kudo K; Horibe K
    Cancer; 1995 Jun; 75(11):2757-61. PubMed ID: 7743482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers.
    Stutterheim J; Gerritsen A; Zappeij-Kannegieter L; Yalcin B; Dee R; van Noesel MM; Berthold F; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
    Clin Chem; 2009 Jul; 55(7):1316-26. PubMed ID: 19460840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TH and DCX mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients.
    Yáñez Y; Hervás D; Grau E; Oltra S; Pérez G; Palanca S; Bermúdez M; Márquez C; Cañete A; Castel V
    J Cancer Res Clin Oncol; 2016 Mar; 142(3):573-80. PubMed ID: 26498952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal disease detection in peripheral blood and bone marrow from patients with non-metastatic neuroblastoma.
    Yáñez Y; Grau E; Oltra S; Cañete A; Martínez F; Orellana C; Noguera R; Palanca S; Castel V
    J Cancer Res Clin Oncol; 2011 Aug; 137(8):1263-72. PubMed ID: 21706131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mRNAs of tyrosine hydroxylase and dopa decarboxylase but not of GD2 synthase are specific for neuroblastoma minimal disease and predicts outcome for children with high-risk disease when measured at diagnosis.
    Träger C; Vernby A; Kullman A; Ora I; Kogner P; Kågedal B
    Int J Cancer; 2008 Dec; 123(12):2849-55. PubMed ID: 18814238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential expression of minimal residual disease markers in peripheral blood and bone marrow samples from high-risk neuroblastoma patients.
    Yamamoto N; Kozaki A; Hartomo TB; Yanai T; Hasegawa D; Kawasaki K; Kosaka Y; Matsuo M; Hirase S; Mori T; Hayakawa A; Iijima K; Nishio H; Nishimura N
    Oncol Lett; 2015 Nov; 10(5):3228-3232. PubMed ID: 26722317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of neuroblastoma-related genes in bone marrow at end of high-risk neuroblastoma therapy.
    Asgharzadeh S; Marachelian A; Villablanca JG; Liu WY; Kennedy R; Sposto R; Naranjo A; Tenney S; Yu AL; Ozkaynak MF; Sondel PM; Park JR; Seeger RC
    Pediatr Blood Cancer; 2022 Sep; 69(9):e29719. PubMed ID: 35441784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PHOX2B is a suppressor of neuroblastoma metastasis.
    Naftali O; Maman S; Meshel T; Sagi-Assif O; Ginat R; Witz IP
    Oncotarget; 2016 Mar; 7(9):10627-37. PubMed ID: 26840262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PHOX2B Is Associated with Neuroblastoma Cell Differentiation.
    Yang L; Ke XX; Xuan F; Tan J; Hou J; Wang M; Cui H; Zhang Y
    Cancer Biother Radiopharm; 2016 Mar; 31(2):44-51. PubMed ID: 26910576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential application of ELAVL4 real-time quantitative reverse transcription-PCR for detection of disseminated neuroblastoma cells.
    Swerts K; De Moerloose B; Dhooge C; Vandesompele J; Hoyoux C; Beiske K; Benoit Y; Laureys G; Philippé J
    Clin Chem; 2006 Mar; 52(3):438-45. PubMed ID: 16384890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential detection of tumor cells in the peripheral blood and bone marrow of patients with stage IV neuroblastoma by the reverse transcription-polymerase chain reaction for tyrosine hydroxylase mRNA.
    Miyajima Y; Horibe K; Fukuda M; Matsumoto K; Numata S; Mori H; Kato K
    Cancer; 1996 Mar; 77(6):1214-9. PubMed ID: 8635146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RT-PCR demonstrates superior sensitivity and specificity in detecting the five neuroblastoma genes compared to the flow cytometry method for measurable residual disease.
    Tian X; Li H; Luo T; Mao J; Yuan X; Gao Q; Xiao J; Qian S; Zou R; Chen K; Zhu C; Yi C; He X
    Transl Pediatr; 2023 Dec; 12(12):2232-2246. PubMed ID: 38197110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.